Texas Ebola patient gets Chimerix therapy

Texas Health Presbyterian Hospital said Monday a patient with Ebola was given brincidofovir from Chimerix Inc. (NASDAQ:CMRX) on Oct. 4. Chimerix said FDA had granted its emergency IND application to investigate brincidofovir to treat Ebola at the behest of physicians. The patient has been in isolation at the hospital since Sept. 29.

On Sunday, CDC Director Tom Frieden said supplies of experimental therapy ZMapp had been exhausted and that the combination of three mAbs targeting Ebola glycoproteins GP1 and GP2 from Mapp Biopharmaceutical Inc. (San Diego, Calif.) is "not going to be available any time soon." ...